SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2020-03-12
Target enrollment:
Participant gender:
Summary
This is a 4-stage, non-randomized, open-label, dose escalation and expansion, multicenter
study. A cycle of therapy is 21 days. Stage 1 was a dose-escalation stage. During Stages 2-4,
patients are treated at the MTD or maximum tested dose at which multiple DLTs are not
observed during Stage 1.